182 related articles for article (PubMed ID: 10944799)
1. Activation of skin dendritic cells by immunostimulatory DNA.
Vogel JC; Udey MC
Springer Semin Immunopathol; 2000; 22(1-2):45-54. PubMed ID: 10944799
[No Abstract] [Full Text] [Related]
2. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.
Ramírez-Pineda JR; Fröhlich A; Berberich C; Moll H
J Immunol; 2004 May; 172(10):6281-9. PubMed ID: 15128817
[TBL] [Abstract][Full Text] [Related]
3. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.
Cote-Sierra J; Bredan A; Toldos CM; Stijlemans B; Brys L; Cornelis P; Segovia M; de Baetselier P; Revets H
Infect Immun; 2002 Jan; 70(1):240-8. PubMed ID: 11748189
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
5. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
[TBL] [Abstract][Full Text] [Related]
6. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge.
Stobie L; Gurunathan S; Prussin C; Sacks DL; Glaichenhaus N; Wu CY; Seder RA
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8427-32. PubMed ID: 10890924
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.
Kronenberg K; Brosch S; Butsch F; Tada Y; Shibagaki N; Udey MC; von Stebut E
J Invest Dermatol; 2010 Nov; 130(11):2602-10. PubMed ID: 20574442
[TBL] [Abstract][Full Text] [Related]
8. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
[TBL] [Abstract][Full Text] [Related]
9. The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers.
Iborra S; Abánades DR; Parody N; Carrión J; Risueño RM; Pineda MA; Bonay P; Alonso C; Soto M
Clin Exp Immunol; 2007 Nov; 150(2):375-85. PubMed ID: 17900304
[TBL] [Abstract][Full Text] [Related]
10. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
Jakob T; Walker PS; Krieg AM; Udey MC; Vogel JC
J Immunol; 1998 Sep; 161(6):3042-9. PubMed ID: 9743369
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice.
Shah JA; Darrah PA; Ambrozak DR; Turon TN; Mendez S; Kirman J; Wu CY; Glaichenhaus N; Seder RA
J Exp Med; 2003 Jul; 198(2):281-91. PubMed ID: 12874261
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen.
Noormohammadi AH; Hochrein H; Curtis JM; Baldwin TM; Handman E
Vaccine; 2001 Jul; 19(28-29):4043-52. PubMed ID: 11427281
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides.
Wu W; Weigand L; Belkaid Y; Mendez S
Eur J Immunol; 2006 Dec; 36(12):3238-47. PubMed ID: 17109471
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens.
Berberich C; Ramírez-Pineda JR; Hambrecht C; Alber G; Skeiky YA; Moll H
J Immunol; 2003 Mar; 170(6):3171-9. PubMed ID: 12626575
[TBL] [Abstract][Full Text] [Related]
16. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
Afonso LC; Scharton TM; Vieira LQ; Wysocka M; Trinchieri G; Scott P
Science; 1994 Jan; 263(5144):235-7. PubMed ID: 7904381
[TBL] [Abstract][Full Text] [Related]
17. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
Coler RN; Skeiky YA; Bernards K; Greeson K; Carter D; Cornellison CD; Modabber F; Campos-Neto A; Reed SG
Infect Immun; 2002 Aug; 70(8):4215-25. PubMed ID: 12117930
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
19. TLR9-dependent activation of dendritic cells by DNA from Leishmania major favors Th1 cell development and the resolution of lesions.
Abou Fakher FH; Rachinel N; Klimczak M; Louis J; Doyen N
J Immunol; 2009 Feb; 182(3):1386-96. PubMed ID: 19155485
[TBL] [Abstract][Full Text] [Related]
20. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.
Tonui WK; Mejia JS; Hochberg L; Mbow ML; Ryan JR; Chan AS; Martin SK; Titus RG
Infect Immun; 2004 Oct; 72(10):5654-61. PubMed ID: 15385463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
